In Brief
Refine Search
Pharmaceutical
Japanese drugmaker Sosei Group Corporation (Sosei Heptares) today announced that its Board of Directors resolved to change the corporate names of the company and its subsidiaries and the location of the head office of the company. 16 February 2024
Pharmaceutical
The European Commission (EC) has published a report providing an overview of the enforcement of European Union antitrust and merger rules by the EC and EU national competition authorities in the pharmaceutical sector between 2018 and 2022. 12 February 2024
Pharmaceutical
February 9, 2024
Sylentis, a wholly owned subsidiary of Spain’s PharmaMar, (has obtained the results of the Phase III SYL10111_V (tivanisiran) clinical trial for the treatment of dry-eye associated with Sjögren’s syndrome. 11 February 2024
Pharmaceutical
Luye Pharma Group has entered into an agreement with Myung In Pharm, granting the latter the exclusive rights to commercialize rivastigmine twice weekly transdermal patch in South Korea. 7 February 2024
Pharmaceutical
The impact of the Corporate Transparency Act on healthcare organizations, increased scrutiny by regulators of private equity investments in healthcare, and the subsectors that are seeing the most mergers and acquisitions, joint ventures and other transactions, are among the topics covered by a new report. 2 February 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application and granted Priority Review for Roche subsidiary Genentech’s ALK inhibitor Alecensa (alectinib) as adjuvant treatment following surgery for early-stage lung cancer (NSCLC). 30 January 2024
Pharmaceutical
German pharma and crop sciences major Bayer saw it shares drop more than 6% to 30.37 euros by early afternoon today, on the news that it has been ordered to pay in damages, the highest amount yet in its ongoing litigation linked to an alleged carcinogenic effect of its Roundup weedkiller. 29 January 2024
Pharmaceutical
USA-based gastroenterology specialist Ironwood Pharmaceuticals announced that new data from the Phase III study that evaluated linaclotide in children and adolescents aged 6-17 years with functional constipation were published in The Lancet Gastroenterology & Hepatology. 15 January 2024
Pharmaceutical
California’s Revagenix has closed a series B funding round from core investors Tenmile and Novo Holdings, raising an undisclosed sum. 8 January 2024
Pharmaceutical
Turbine AI, a UK-based biological simulation company building a platform for interpreting human biology in silico, has entered into a collaboration with British pharma major AstraZeneca. 6 January 2024
Pharmaceutical
Denmark’s Union Therapeutics has said that its chief executive, Kim Kjøller, will be making a presentation at the JP Morgan Healthcare Conference on January 8. 5 January 2024
Pharmaceutical
The British business of Italian drugmaker Menarini has been granted marketing authorization for Korserdu (elacestrant) in the UK. 3 January 2024
Pharmaceutical
Swedish biotech Calliditas Therapeutics has announced that it has refinanced its debt to the tune of $102 million, shortly after Tarpeyo (budesonide) received regular approval in the USA. 28 December 2023
Pharmaceutical
US pharma major Eli Lilly today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares of POINT Biopharma Global. 20 December 2023
Pharmaceutical
Irish-American specialty pharma company Shorla Oncology and Eversana, a provider of commercialization services to the life sciences industry, have announced the US commercial launch of Jylamvo (methotrexate) oral solution, the first and only oral methotrexate solution approved in the USA for use in adults. 19 December 2023
Pharmaceutical
Today, New York-based Neurogene, a specialist in rare neurological diseases, announced the close of its merger with Neoleukin Therapeutics they announced in July, and has begun trading on the NASDAQ Global Market under the ticker “NGNE.” 19 December 2023
Pharmaceutical
US pharma major AbbVie has announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust pipeline. of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain. 7 December 2023
Pharmaceutical
Japanese drugmaker Teijin Pharma as enter into an exclusive licensing agreement with Denmark’s Ascendis Pharma regarding the research, development, manufacturing and sales in Japan. 30 November 2023
Pharmaceutical
Two American firms, Evommune and Accutar Biotechnology, have announced a strategic partnership focused on the discovery of novel small molecules in chronic inflammatory diseases. 29 November 2023
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk today announced the investment of more than 16 billion Danish kroner ($2.3 billion) starting in 2023 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases. 23 November 2023
Pharmaceutical
The UK’s National Institute of Health and Care Excellence (NICE) has recommended erdafitinib, trade name Balversa and manufactured by Johnson & Johnson, for some adult patients in England. 10 April 2025
Pharmaceutical
At the recent American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation associated with Alzheimer’s disease (AD). 10 April 2025
Pharmaceutical
The first comprehensive analysis of clinical trials in the UK has found the country remains a global leader in medical research but highlights the need for broader disease focus and better trial representation. 10 April 2025
Pharmaceutical
Danish pharma major Novo Nordisk has announced an investment of $1.1 billion to expand its production facility in Brazil’s Montes Claros, northern Minas Gerais, with the aim of increasing production capacity for injectable treatments for people with obesity, diabetes and other serious chronic diseases. 10 April 2025
Pharmaceutical
US health technology assessor the Institute for Clinical and Economic Review (CER), in collaboration with researchers from Brown University, has published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications. 10 April 2025
Pharmaceutical
The All-Russian Union of Patients (VSP) has called on Russia’s Deputy Prime Minister, Tatyana Golikova, to expand the list of drugs that are the subject of public procurements in the country in order to avoid a shortage of certain categories of drugs in the domestic market, The Pharma Letter’s local correspondent reports.. 10 April 2025
Pharmaceutical
The Russian pharmaceutical market grew by 10% in value terms to 2.85 trillion roubles ($85 billion) in 2024, which was mainly due to the growth of it commercial segment, where the growth of sales was equivalent to 13.8%. 9 April 2025
Pharmaceutical
The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma major AbbVie , for the treatment of giant cell arteritis (GCA) in adult patients. 9 April 2025
Pharmaceutical
US biotech Annovis Bio has reported encouraging findings for its experimental therapy buntanetap in a subgroup of patients with early-stage Parkinson’s disease and mild dementia. 9 April 2025
Pharmaceutical
Swiss biopharma Idorsia has received approval from the US Food and Drug Administration for an updated label on its hypertension drug Tryvio (aprocitentan), removing the previous Risk Evaluation and Mitigation Strategy requirement. 9 April 2025
Pharmaceutical
Shares of USA and UK-based KalVista Pharmaceuticals fell 4% to $11.04 yesterday, despite the company revealing it has signed a licensing deal for the commercialization rights in Japan to Kaken Pharmaceutical for sebetralstat, an investigational, oral on-demand treatment for hereditary angioedema (HAE). 9 April 2025
Pharmaceutical
The uveitis treatment market across seven major markets—the USA, France, Germany, Italy, Spain, the UK, and Japan—is projected to grow from $522 million in 2023 to $1.5 billion by 2033, according to a report from data analytics firm GlobalData. This marks an annual growth rate of nearly 11%. 8 April 2025
Pharmaceutical
In the USA, the layoffs at health agencies, proposed tariffs on imports and other disruptive policies under President Donald Trump have led some to express concern over a potential ‘brain drain’ impacting pharma and other industries. 8 April 2025
Pharmaceutical
US biopharma Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase III TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of acquired hypothalamic obesity. 8 April 2025
Pharmaceutical
Indian drugmaker Sun Pharmaceutical Industries revealed it has launched fexuprazan tablets 40mg in India under the brand name Fexuclue, which is a novel potassiumcompetitive acid blocker (PCAB) that is approved as a new treatment for adults with erosive esophagitis of all grades. 8 April 2025
Pharmaceutical
Ireland’s government remains confident in its ability to retain the country’s strategic position in pharmaceutical manufacturing, despite rising tensions between the European Union and the United States over trade policy. 8 April 2025
Pharmaceutical
At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in development for early PD, failed to meet its primary endpoint in the Phase II ASCEND trial as a monotherapy. 8 April 2025
Pharmaceutical
US biotech company Vertex Pharmaceuticals has received European Commission approval to extend the use of its cystic fibrosis therapy, Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with ivacaftor. 8 April 2025
Pharmaceutical
The USA’s Centers for Medicare & Medicaid Services (CMS) yesterday released the Calendar Year (CY) 2026 Rate Announcement for the Medicare Advantage (MA) and Medicare Part D Prescription Drug Programs that finalizes the payment policies for these programs. 8 April 2025
Pharmaceutical
US biotech start-up RayThera has secured $110 million in series A financing to fund the early clinical development of its small molecule drug candidates in immunology. 8 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze